Drug pricing probes pressure companies

Jun 21, 2016
China’s antitrust regulator has launched an official investigation campaign to unravel the complex supply and distribution networks of drugs and medical devices. Healthcare firms will need to ensure proper pricing conduct and prepare for the surveys and raids

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
 

The National Development and Reform Commission (NDRC) has formally launched a nationwide pricing investigation into China’s pharmaceutical and medical devices industries.

This premium content is reserved for
China Law & Practice Subscribers.

A Premium Subscription Provides:

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment

SUBSCRIBE NOW

Subscribe Now

For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected].